Biobusiness Development Grants Awarded

Biobusiness grants help develop Minnesota businesses and infrastructure to deliver regenerative medicine products and services. Learn more about how to apply for a biobusiness grant by reading our frequently asked questions. 

 

View bio business grants awarded by year.
Artur Serebrenik, PhD
Artur Serebrenik, PhD
Development of BIO 300 as a regenerative therapy for triple negative breast cancer
The primary goal of the proposed work is to produce preclinical data to support the use of BIO 300 in patients with triple negative breast cancer…
2021-2022
Ross Dunbar
Ross Dunbar
The Isthmus Foundation commercialization of Rapidly Endothelialized Vascular Bypass Grafts and Liquid-Nitrogen Free Cryopreservation Storage System
Our goal is focused on developing the commercial pathway for two translational stem cell related projects in Minnesota, one creating Rapidly…
2021-2022
Athanasiou
Maria Athanasiou, PhD
Regenerative Medicine for the Durable Remission of HIV, Plasmid Infrastructure
We are developing a one-time treatment for durable remission of HIV in the absence of antiretroviral treatment. This treatment is a regenerative…
2021-2022
Lab group
Timothy O'Brien, DVM, PhD
Pre‐clinical Development of Organoid‐derived Chondrocyte Product for Articular Cartilage Repair
We have developed a technically simple, scalable, cGMP‐compatible method to generate hyaline cartilage from human induced pluripotent stem cells.…
2020-2021
Wesley A. Wierson, PhD
Wesley Wierson, PhD
Translational and Regenerative Immunotherapy for Spontaneous Disease in Dogs
LEAH Labs is bringing regenerative immunotherapy to dogs. We use gene editing to enable the translation of cell therapies from successful…
2020-2021
Dave Roeser
Dave Roeser
Molecular Farming of BMPs and Fibronectin for Commercialization
We have seven specific milestones with the goal of making bone morphogenetic protein and fibronectin (used to promote bone repair) that…
2020-2021
Timothy D. O'Brien, DVM, PhD
Timothy O'Brien, DVM, PhD
Pre‐clinical Development of Organoid‐derived Chondrocyte Product for Articular Cartilage Repair
We have developed a technically simple, scalable, cGMP‐compatible method to generate hyaline cartilage from human induced pluripotent stem cells.…
2020-2021
Amir Naqwi
Amir Naqwi, PhD
Airway Cell Delivery with Visualization
We are proposing the development of an airway cell sprayer that would be included in the instrument channel of a bronchoscope for depositing viable…
2020-2021
Maria Athanasiou
Maria Athanasiou, PhD
Regenerative Medicine for the Durable Remission of HIV
Building on successful primate model studies, MarPam Pharma is developing a one‐time treatment for durable remission of HIV in the absence of…
2020-2021
image of Patrick Walsh
Patrick Walsh, MS
Extending the Anatomi Corp differentiation ecosystem for the production of hiPSC derived neuronal subtypes
The goal of this grant is to bring Anatomi Corp's Chrono™ Platform to market. A small portion of this funding will offset overhead costs associated…
2019-2020
image of Neil Otto, PhD
Neil Otto, PhD
Amaxa LV Unit for engineered therapeutic cells for regenerative medicine
The ultimate goal is to provide our gene transfer transposon/transposase platforms to the rapidly growing field of gene modified cell therapy. B‐…
2019-2020
Timothy O'Brien, DVM, PhD
Development of organoid-derived chondrocyte products for articular cartilage repair
We have developed a novel technology that induces human stem cells to form cartilage. In this project we aim to take the first steps in developing…
2019-2020